Rifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 Diabetes

Last updated: November 28, 2018
Sponsor: Zagazig University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hormone Deficiencies

Diabetes (Pediatric)

Hypertriglyceridemia

Treatment

N/A

Clinical Study ID

NCT03758144
4493
  • Ages 18-60
  • All Genders

Study Summary

Gut Dysbiosis had been involved in some way in the pathogenesis of some extra-intestinal disorders including metabolic syndrome, cardiovascular disease, and obesity.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • diabetes with gut dysbiosis

Exclusion

Exclusion Criteria:

  • recent antibiotic use

  • pregnancy

  • diabetogenic drugs

Study Design

Total Participants: 80
Study Start date:
November 01, 2018
Estimated Completion Date:
July 01, 2019

Study Description

Accumulating evidence had linked metabolic syndrome and diabetes to dysequilibrium in gut microbiota, which are a critical regulator of host metabolism and immune responses. gut microbiota interacts with host signaling pathways, leading to modulation of the endocrine system, immune responses. gut microbial metabolites, in particular, short-chain fatty acids, have been significantly associated with liability to diabetes. patients with positive fecal short-chain fatty acids will be given rifaximin

Connect with a study center

  • Zagazig University

    Zagazig, Sharkia 44519
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.